Senazodan

Drug Profile

Senazodan

Alternative Names: MCI 154

Latest Information Update: 27 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
  • Class Cardiotonics
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure

Most Recent Events

  • 27 May 2010 Discontinued - Phase-II for Acute heart failure in Japan (PO)
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 20 Mar 2006 Senazodan is available for licensing worldwide(http://www.micusa.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top